|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 1998
Clinical Trial |
Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group
Alpha1-antitrypsin (alpha1-AT) deficiency is a genetic disorder characterized by low serum levels of alpha1-AT and a high risk of pulmonary emphysema at a young age. The resulting surplus of proteases, mainly of neutrophil elastase, can be balanced by i.v. augmentation with alpha1-AT. However, it is not clear if affected patients benefit from long-term augmentation therapy and no long-term safety data are available. We examined 443 patients with severe alpha1-AT deficiency and pulmonary emphysema receiving weekly i.v. infusions of 60 mg x kg body weight(-1) alpha1-AT in addition to their regular medication. The progression of the disease was assessed by repeated lung function measurements, particularly the decline in forced expiratory volume in one second (deltaFEV1). Four hundred and forty three patients with alpha1-AT deficiency tolerated augmentation therapy well with few adverse reactions. The deltaFEV1 in 287 patients with available follow-up data was 57.1+/-31.1 mL x yr(-1). Stratified for baseline FEV1, the decline was 35.6+/-21.3 mL in the 108 patients with an initial FEV1 <30% and 64.0+/-26.4 mL in the 164 with FEV1 30-65% of predicted normal (p=0.0008). The remaining 15 patients had an initial FEV1 >65% pred. Long-term treatment with i.v. alpha1-antitrypsin in patients with severe alpha1-antitrypsin deficiency is feasible and safe. The decline in forced expiratory volume in one second is related to the initial forced expiratory volume in one second as in alpha1-antitrypsin deficient patients not receiving augmentation therapy.
This article has been cited by other articles:
|
|
 |
|
  B. Gooptu, U. I. Ekeowa, and D. A. Lomas Mechanisms of emphysema in {alpha}1-antitrypsin deficiency: molecular and cellular insights Eur. Respir. J., August 1, 2009; 34(2): 475 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Griese and H. Bruggen Intravenous {alpha}1-antitrypsin in a child with deficiency and severe lung disease Eur. Respir. J., July 1, 2009; 34(1): 278 - 279. [Full Text] [PDF]
|
|
|
|
|
|
A. Dirksen, E. Piitulainen, D. G. Parr, C. Deng, M. Wencker, S. B. Shaker, and R. A. Stockley Exploring the role of CT densitometry: a randomised study of augmentation therapy in {alpha}1-antitrypsin deficiency Eur. Respir. J., June 1, 2009; 33(6): 1345 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Stoller and L. S. Aboussouan Myths and Misconceptions About {alpha}1-Antitrypsin Deficiency Arch Intern Med, March 23, 2009; 169(6): 546 - 550. [Full Text] [PDF]
|
|
|
|
 |
|
 D Soy, C de la Roza, B Lara, C Esquinas, A Torres, and M Miravitlles Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics Thorax, December 1, 2006; 61(12): 1059 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Sandhaus {alpha}1-Antitrypsin deficiency {middle dot} 6: New and emerging treatments for {alpha}1-antitrypsin deficiency Thorax, October 1, 2004; 59(10): 904 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J K Stoller and L S Aboussouan {alpha}1-Antitrypsin deficiency {middle dot} 5: Intravenous augmentation therapy: current understanding Thorax, August 1, 2004; 59(8): 708 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 818 - 900. [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Stoller, R. Fallat, M. D. Schluchter, R. G. O'Brien, J. T. Connor, N. Gross, K. O'Neil, R. Sandhaus, and R. G. Crystal Augmentation Therapy With {alpha}1-Antitrypsin: Patterns of Use and Adverse Events Chest, May 1, 2003; 123(5): 1425 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wencker, A. Marx, N. Konietzko, B. Schaefer, and E.J. Campbell Screening for {alpha}1-Pi deficiency in patients with lung diseases Eur. Respir. J., August 1, 2002; 20(2): 319 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Stoller, F. Rouhani, M. Brantly, S. Shahin, R. A. Dweik, J. M. Stocks, J. Clausen, E. Campbell, and F. Norton Biochemical Efficacy and Safety of a New Pooled Human Plasma {alpha}1-Antitrypsin, Respitin* Chest, July 1, 2002; 122(1): 66 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. W. Burdon, S. Brenton, M. Ayad, K. Knight, and J. Lieberman Augmentation Therapy in {alpha}1-Antitrypsin Deficiency Chest, August 1, 2001; 120(2): 687 - 687. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kropp, M. Wencker, A. Hotze, N. Banik, G. E. Hubner, G. Wunderlich, E. Ulbrich, N. Konietzko, and H.-J. Biersack Inhalation of [123I]{{alpha}}1-Protease Inhibitor: Toward a New Therapeutic Concept of {{alpha}}1-Protease Inhibitor Deficiency? J. Nucl. Med., May 1, 2001; 42(5): 744 - 751. [Abstract] [Full Text]
|
|
|
|
|
|
M. Wencker, B. Fuhrmann, N. Banik, and N. Konietzko Longitudinal Follow-up of Patients With {{alpha}}1-Protease Inhibitor Deficiency Before and During Therapy With IV {{alpha}}1-Protease Inhibitor Chest, March 1, 2001; 119(3): 737 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Alkins and P. O’Malley Should Health-Care Systems Pay for Replacement Therapy in Patients With {alpha}1-Antitrypsin Deficiency?: A Critical Review and Cost-Effectiveness Analysis Chest, March 1, 2000; 117(3): 875 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J KROWKA Hepatopulmonary syndromes Gut, January 1, 2000; 46(1): 1 - 4. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |